A Blood Test Can Detect 10 Cancers Before Symptoms Develop
A Blood Test Can Detect 10 Cancers Before Symptoms Develop.
A blood test is a laboratory analysis performed on a blood sample that is usually extracted from a vein in the arm using a hypodermic needle, or via fingerprick. But according to a new discovering, blood test can now detect many types of cancer, to what is known as a liquid biopsy, is used to screen for DNA.
A new blood test shows promise for detecting many types of cancer, the research enables scientists to use a blood test to screen for different types of cancers at early stages. The test, known as a liquid biopsy, is used to screen for DNA from cancer cells and was able to detect 10 different cancers and it was 80 to 90 percent accurate.
- I am sure You are transform by the information you get through me, I am also sure you can be part of our daily updates. why not leave your email behind let me keep you informed with information, jobs and inspire you always.
However, much more research is needed before doctors will be able to use the test on their patients, experts say. The non-invasive DNA blood test isn’t yet ready to use in practice, but the test would enable cancers to be detected in the early stages, before symptoms begin, when treatment is more likely to succeed. These types of tests could become part of a universal screening process for cancer.
“This is a very promising study,” said Dr. Kazuaki Takabe, the Alfiero Foundation endowed chair in breast oncology at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, who was not involved with the study. However, Takabe stressed that the work is very preliminary. “Clearly, this is just the beginning,” Takabe said. “We need more and more and more samples” to determine the true accuracy of the test.
The research sampled 1,627 participants, of which 749 were cancer-free and 878 had various types of newly detected, untreated cancer. The blood test involved three tests on the participants’ blood samples and showed sensitivity in detecting 10 different types of cancer, including pancreatic, ovarian, lung and esophageal cancer, among others.
The test’s high sensitivity to pancreatic cancer is especially promising. Pancreatic cancer is usually diagnosed when the cancer is too advanced to be operated on, said Dr. Chris Abbosh, a clinical research associate at University College London’s Cancer Institute. However, it’s important to note that the number of people in which these cancers were detected was small. For both ovarian and pancreatic cancer, only 10 cases were detected, while only five people with hepatobiliary cancer were identified. Head and neck cancer as well as lung cancer were detected with the least accuracy, at 56% and 59%, respectively.
In addition, the study included patients who had already been diagnosed with cancer, so more studies are needed to investigate whether the test can detect cancer in its earliest stages, before people are typically diagnosed with the disease. The study, led by researchers at the Cleveland Clinic Taussig Cancer Institute, will be presented June 4 at the annual meeting of the American Society of Clinical Oncology in Chicago.
Takabe noted that although the study included more than 1,600 patients, the number of patients with some types of cancers was quite small — for example, only about 10 patients in the study had ovarian cancer — which is another limitation of the study.
“The vast majority of medical practice is based upon chief complaint,” meaning a patient’s first report that’s something’s wrong, Takabe said, adding, “The excitement about these liquid biopsies is, can we screen people who have absolutely no symptoms, no complaints” but have something in their blood that could hint at cancer?
Some researchers have criticized the idea of liquid biopsies because it’s unclear whether catching cancer very early would indeed prolong a person’s life, Takabe noted. However, developing technology to detect the disease very early would hopefully lead to the “discovery of measures that truly prolong life when those disease[s] are detected super early.”
Mesothelioma Survival Rate
Approximately 55 % of mesothelioma patients live longer than 6 months, while nearly 35 percent live longer than a single year. Only 9% of people diagnosed with mesothelioma survive longer than 5 years.
What Is Survival Rate?
Mesothelioma survival rate refers to the percentage of humans who live a certain amount of time after receiving full mesothelioma diagnosis. The 5-year survival rate is a standard statistic used for many types of cancer. However, because mesothelioma cancer is so deadly, many people also refer to 1-year survival rates, as well.
Survival rate should not be astonished with life expectancy, which refers to the total average length of time patients with mesothelioma would live. Together, both of these statistics can provide information about an individual’s prognosis.
Survival rate also should not be astonished with mesothelioma mortality rate. Mortality rate is a statistic used by health organizations and governmental agencies to understand the prevalence of a disease in a given area (such as a country, state or city).